CRISPR Gene-Edited immune cells aim to fight lung cancer – but trial never started
Disease control
Terminated
This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the tria…
Phase: PHASE1, PHASE2 • Sponsor: Intima Bioscience, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC